Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Guided Therapeutics (GTHP) over the last 12 years, with Q3 2025 value amounting to $29000.0.

  • Guided Therapeutics' Non-Current Debt fell 4528.3% to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $29000.0, marking a year-over-year decrease of 4528.3%. This contributed to the annual value of $47000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Guided Therapeutics' Non-Current Debt stood at $29000.0, which was down 4528.3% from $35000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Non-Current Debt ranged from a high of $592000.0 in Q4 2021 and a low of $29000.0 during Q3 2025
  • In the last 4 years, Guided Therapeutics' Non-Current Debt had a median value of $87500.0 in 2022 and averaged $245642.9.
  • As far as peak fluctuations go, Guided Therapeutics' Non-Current Debt plummeted by 69.32% in 2021, and later tumbled by 8597.97% in 2022.
  • Quarter analysis of 4 years shows Guided Therapeutics' Non-Current Debt stood at $592000.0 in 2021, then crashed by 85.98% to $83000.0 in 2022, then tumbled by 43.37% to $47000.0 in 2024, then plummeted by 38.3% to $29000.0 in 2025.
  • Its last three reported values are $29000.0 in Q3 2025, $35000.0 for Q2 2025, and $41000.0 during Q1 2025.